DDX53 and neoplasm: According to previous literature, in the several syngeneic tumor models for testing the αPD-L1 immunotherapy, including the tumors derived by CT26, RENCA, 4T1, B16F10 AP3, LL/2, and MC38, there is only CT26 sensitized to αPD-L1 immunotherapy [24].